Jubilant Ingrevia Records Strong Q2 FY27: Revenue At ₹1,394 Crore, PAT Surges 61%, ZettaOne Stake Acquired

Mumbai: In its second quarter results for fiscal year 2027, Jubilant Ingrevia Limited showcased impressive financial performance. The company's total revenue surged to ₹1,394 crore, a notable increase from ₹1,121 crore in the same period last year. Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) climbed by 51% to ₹221 crore, while Basic and Diluted Earnings Per Share (EPS) rose by 61% to ₹7.1.

For the first half of fiscal year 2027, Jubilant Ingrevia reported total revenue of ₹2,695 crore, marking a 25% increase year-on-year. EBITDA expanded by 44% to ₹431 crore, while Profit After Tax (PAT) grew by 50% to ₹217 crore.

The company announced its acquisition of a 40% stake in ZettaOne Technologies Limited. This move places Jubilant Ingrevia in the Electronic Design and Manufacturing Services (EDMS) sector.

Shyam S Bhartia, Chairman, and Hari S Bhartia, Co-Chairman, Jubilant Ingrevia, expressed satisfaction, stating, "Our quarterly EBITDA has more than doubled in three years, reflecting the successful execution of our Pinnacle strategy and disciplined cost management."

CEO and Managing Director Deepak Jain attributed the robust performance to the company's adept handling of market disruptions and price volatility. Segmented results revealed the Specialty Chemicals segment growing by 16% year-on-year and the Nutrition business increasing by 50%. The Chemical Intermediates segment also showed a 24% year-on-year increase.

Despite stable volumes and improved realisations, higher input and utility costs slightly impacted the company's margins. The pharmaceutical sector experienced steady demand for intermediates during this period.